Michael King
Stock Analyst at Rodman & Renshaw
(0.89)
# 3,878
Out of 5,182 analysts
103
Total ratings
36.21%
Success rate
-10.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Initiates: Buy | $17 | $1.26 | +1,249.21% | 1 | Mar 17, 2026 | |
| KPTI Karyopharm Therapeutics | Initiates: Buy | $28 | $9.30 | +201.08% | 1 | Mar 10, 2026 | |
| ELTX Elicio Therapeutics | Initiates: Buy | $17 | $10.77 | +57.85% | 1 | Mar 10, 2026 | |
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $16.47 | +3,847.65% | 4 | Apr 1, 2024 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $2.23 | +393.27% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.48 | +2,062.16% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $0.99 | +6,848.67% | 10 | Jun 12, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $0.69 | +1,102.90% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $709.21 | +21.54% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $44.17 | -45.66% | 10 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $166 | $4.02 | +4,029.35% | 8 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $13.36 | +214.37% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $297.93 | +2.04% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $13.87 | +736.34% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.94 | +430.93% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $46.41 | -48.29% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $69.78 | -34.08% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $27.48 | +249.34% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $504 | $8.47 | +5,853.93% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $36.73 | -15.60% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $811.09 | -95.56% | 2 | Nov 13, 2017 |
BioXcel Therapeutics
Mar 17, 2026
Initiates: Buy
Price Target: $17
Current: $1.26
Upside: +1,249.21%
Karyopharm Therapeutics
Mar 10, 2026
Initiates: Buy
Price Target: $28
Current: $9.30
Upside: +201.08%
Elicio Therapeutics
Mar 10, 2026
Initiates: Buy
Price Target: $17
Current: $10.77
Upside: +57.85%
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $16.47
Upside: +3,847.65%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $2.23
Upside: +393.27%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.48
Upside: +2,062.16%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $0.99
Upside: +6,848.67%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $0.69
Upside: +1,102.90%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $709.21
Upside: +21.54%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $44.17
Upside: -45.66%
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $4.02
Upside: +4,029.35%
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $13.36
Upside: +214.37%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $297.93
Upside: +2.04%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $13.87
Upside: +736.34%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $1.94
Upside: +430.93%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $46.41
Upside: -48.29%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $69.78
Upside: -34.08%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $27.48
Upside: +249.34%
Jan 10, 2022
Initiates: Buy
Price Target: $504
Current: $8.47
Upside: +5,853.93%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $36.73
Upside: -15.60%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $811.09
Upside: -95.56%